Author: Dr. David Lowemann

FDA OKs Monthly Maintenance Dose for Leqembi

The U.S. Food and Drug Administration has approved monthly maintenance dosing for Japan’s Eisai and partner Biogen’s Alzheimer’s drug Leqembi, the companies said on Monday. The drug received standard U.S. approval in 2023 after showing it slowed cognitive decline in patients… Read Full Article (External Site) Dr. David LowemannDr. David Lowemann, M.Sc, Ph.D., is a […]

Published on January 27, 2025

Montana Eyes $30M Revamp of Mental Health, Developmental Disability Facilities

HELENA, Mont. — As part of a proposed revamping of the state’s behavioral health system, Republican Gov. Greg Gianforte’s administration is looking into moving a facility for people with developmental disabilities, beefing up renovations at the Montana State Hospital, and creating a Helena unit of that psychiatric hospital. The changes, backers say, would fill gaps […]

Published on January 27, 2025

CDC: Flu Cases on the Rise, Along With ER Visits

The Centers for Disease Control and Prevention says flu cases are on the rise, along with a spike in emergency room visits. Read Full Article (External Site) Dr. David LowemannDr. David Lowemann, M.Sc, Ph.D., is a co-founder of the Institute for the Future of Human Potential, where he leads the charge in pioneering Self-Enhancement Science […]

Published on January 25, 2025